Fyn Signaling in Ischemia-Reperfusion Injury: Potential and Therapeutic Implications by Fang Du, Tao Tang, Qingzhu Li, Jiaxin Liu

“…Fyn is a nonreceptor tyrosine kinase belonging to the Src family of kinases (SFKs), which is related to many normal and pathological processes of the nervous system, including neurodevelopment and disease progression. …”
Get full text

Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis by D. V. Garbuzenko

“…It is shown that, so far, only tyrosine kinase inhibitors have been tested in patients with liver cirrhosis as an antiangiogenic therapy for portal hypertension. …”
Get full text

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma by Jeannette C. Oosterwijk-Wakka, Liesbeth Houkes, Loes F.M. van der Zanden, Lambertus A.L.M. Kiemeney, Kerstin Junker, Anne Y Warren, Tim Eisen, Ulrich Jaehde, Marius T Radu, Rob Ruijtenbeek, Egbert Oosterwijk

“…Introduction: Treatment with Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor (TKI) has increased the progression-free survival (PFS) and overall-survival (OS) of patients with metastasized renal cell carcinoma (mRCC). …”
Get full text

Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy by Karoline Mayer-Pickel, Sabine Horn, Uwe Lang, Mila Cervar-Zivkovic

“…An imbalance of angiogenic and antiangiogenic placental factors such as endoglin and soluble fms-like tyrosine kinase 1 has been implicated in the pathophysiology of preeclampsia. …”
Get full text

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment by S. Lanfranconi, S. Corti, P. Baron, G. Conti, L. Borellini, N. Bresolin, A. Bersano

“…Muscle-specific tyrosine kinase- (MuSK-) antibodies-positive Myasthenia Gravis accounts for about one third of Seronegative Myasthenia Gravis and is clinically characterized by early onset of prominent bulbar, neck, shoulder girdle, and respiratory weakness. …”
Get full text

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias by Alessandro Morotti, Giovanna Carrà, Cristina Panuzzo, Sabrina Crivellaro, Riccardo Taulli, Angelo Guerrasio, Giuseppe Saglio

“…BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. …”
Get full text

Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature by Bader Alharbi, Samer Alamri, Ahmed Mahdi, Siham Marghalani

“…Dasatinib is an oral second-generation multitarget tyrosine-kinase inhibitor (TKI) that is efficacious in treating imatinib-resistant chronic myeloid leukemia (CML) or intolerant cases. …”
Get full text

Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns by Maria Portelli, Byron Baron

“…The clinical presentation of PE and data gathered for the biochemical markers placental growth factor (PlGF), soluble Feline McDonough Sarcoma- (fms-) like tyrosine kinase-1 (sFlt-1), asymmetric dimethylarginine (ADMA), and methyl-lysine is being reviewed with the aim of providing both a clinical and biochemical understanding of how these biomarkers might assist in the diagnosis of PE or indicate its severity.…”
Get full text

Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature by Kirsten C. Webb, Magdalena Harasimowicz, Monica Janeczek, Jodi Speiser, James Swan, Rebecca Tung

“…Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. …”
Get full text

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma by Masaud Shah, Muhammad Hussain, Hyun Goo Woo

“…While traditional approaches like surgical resection and tyrosine kinase inhibitors struggle against the tumor’s immune evasion, monoclonal antibody (mAb)-based immunotherapies have emerged as promising alternatives. …”
Get full text

Co-Expression of Plexin-B1 and Met in Human Breast and Ovary Tumours Enhances the Risk of Progression by Guido Valente, Giuseppina Nicotra, Marisa Arrondini, Roberta Castino, Lorena Capparuccia, Maria Prat, Simonetta Kerim, Luca Tamagnone, Ciro Isidoro

“…The binding of Sema4D to Plex-B1 can trigger the activation of Met tyrosine kinase, thereby promoting cell dissociation and invasive growth. …”
Get full text

Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia by Mireille Crampe, Claire Andrews, Anne Fortune, Stephen E. Langabeer

“…The introduction of the tyrosine kinase inhibitor (TKI) imatinib has revolutionised the outlook of chronic myeloid leukemia (CML); however, a significant proportion of patients develop resistance through several mechanisms, of which acquisition of ABL1 kinase domain mutations is prevalent. …”
Get full text

Rapid Evaluation of Mutant Exon-11 in c-kit in a Recurrent MCT Case Using CD117 Immunocytofluorescence, FACS-Cell Sorting, and PCR by Dettachai Ketpun, Achariya Sailasuta, Prapruddee Piyaviriyakul, Nattawat Onlamoon, Kovit Pattanapanyasat

“…The owner and the veterinarian would like to use a tyrosine kinase inhibitor (TKI) for the dog. Therefore, fine-needle aspiration (FNA) was performed to collect the MCT cells and these cells were submitted to our laboratory for the detection of internal-tandem-duplicated (ITD) mutation of exon-11 in c-kit, prior to the treatment. …”
Get full text

Detection of fusion events by RNA sequencing in FFPE versus freshly frozen colorectal cancer tissue samples by Maxim Sorokin, Maxim Sorokin, Maxim Sorokin, Maxim Sorokin, Vladimir Lyadov, Vladimir Lyadov, Vladimir Lyadov, Maria Suntsova, Marat Garipov, Anna Semenova, Natalia Popova, Egor Guguchkin, Rustam Heydarov, Marianna Zolotovskaia, Xiaowen Zhao, Qing Yan, Ye Wang, Evgeny Karpulevich, Anton Buzdin, Anton Buzdin, Anton Buzdin, Anton Buzdin

“…Specific targeted therapies are available for several types of cancer fusions including receptor tyrosine kinase gene moieties. RNA sequencing (RNAseq) can directly be used for detection of gene rearrangements in a single test, along with multiple additional biomarkers. …”
Get full text

Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application by Kaichun Li, Jin Li

“…Second-line treatment of advanced gastric cancer with ramucirumab, an antibody targeting VEGFR-2, alone or in combination with paclitaxel, has been proved to provide a beneficial effect. The VEGFR-2 tyrosine kinase inhibitor, apatinib, can improve the survival of advanced gastric cancer patients after second-line chemotherapy failure. …”
Get full text

Inhibition of IGF-1R-Dependent PI3K Activation Sensitizes Colon Cancer Cells Specifically to DR5-Mediated Apoptosis But Not to rhTRAIL by Bodvael Pennarun, Jan H. Kleibeuker, Tjitske Oenema, Janet H. Stegehuis, Elisabeth G.E. de Vries, Steven de Jong

“…We hypothesized that inhibiting the IGF-1 receptor (IGF-1R) using NVP-AEW541, a small molecular weight tyrosine kinase inhibitor of the IGF-1R, could increase death receptor (DR)-mediated apoptosis in colon cancer cells.…”
Get full text

Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin by Ping Gu, Jennifer Wu, Elliot Newman, Franco Muggia

“…In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. …”
Get full text

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy by Ensi Voshtina, Huiya Huang, Renju Raj, Ehab Atallah

“…A common first-line therapy offered to qualifying patients includes ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase. Treatment of CLL with ibrutinib therapy is generally well tolerated; however, serious opportunistic infections are being reported in patients treated with ibrutinib. …”
Get full text

Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm by Gary M. Woods, Rajinder P. S. Bajwa, Samir B. Kahwash, Terri Guinipero

“…Myeloproliferative neoplasms (MPNs) are a group of clonal disorders characterized by hyperproliferation of hematologic cell lines and have been associated with tyrosine kinase JAK2-V617F mutations. Secondary acute myeloid leukemia (sAML) is a known complication of JAK2-V617F+ MPNs and bears a poor prognosis. …”
Get full text

Severe Erosive Pill Esophagitis Induced by Crizotinib Therapy: A Case Report and Literature Review by Patrick Jung, Kyle J. Fortinsky, Zane R. Gallinger, Piero Tartaro

“…Previous case reports have described esophagitis thought to be secondary to crizotinib, an oral tyrosine-kinase inhibitor used in the treatment of anaplastic lymphoma kinase- (ALK-) positive non-small cell lung cancer (NSCLC). …”
Get full text